Elanco Animal Health Incorporated announced that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders. The Board expects to seek shareholder approval at the 2024 Annual Meeting of Shareholders for amendments to the Company’s Articles of Incorporation that will: Commence a process to declassify the Board of Directors; Allow shareholders to amend the Company’s Bylaws; and allow shareholders under certain circumstances to call special meetings of shareholders. More information regarding the proposals requiring shareholder approval will be included in the Company’s proxy statement to be filed with the SEC prior to the 2024 Annual Meeting of Shareholders.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELAN:
- Elanco says first shipments of Varenzin-CA1 conditionally approved by FDA
- Elanco price target raised to $13 from $9 at Piper Sandler
- Elanco (NYSE:ELAN) Gains On Robust Q2 Showing; Boosts Guidance
- Elanco sees Q3 adjusted EPS 8c-13c, consensus 16c
- Elanco raises FY23 adjusted EPS view to 80c-89c from 76c-83c, consensus 80c